KalVista Pharmaceuticals (KALV) Tops Q3 EPS by 23c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.75), $0.23 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits